External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

AIBD 2024

-
Coming soon
07:30 PM
Duration 24hrs Orlando, USA
RO7790121 as Treatment for Moderate to Severely Active Ulcerative Colitis: Efficacy and First Quality of Life Results from the Phase 2b TUSCANY-2 Trial
Yarur A, Allegretti JR, Feagan B, Danese S, Schreiber S, Peyrin-Biroulet L, Kierkus J, Leong RW, Bojic D, Lasch K, Schiffman C, Jairath V

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar